Opus Genetics is trading 7.1% up at $3.30 in pre-market, extending its recent rebound after closing at $3.08 on July 24.
- The gain appears to be a technical bounce driven by broader risk-on sentiment in U.S. futures, as no company-specific headlines or FDA updates have been released.
- Major news feeds and investor relations channels show no new announcements or earnings reports directly linked to the current price action.